AIDX — 20/20 Biolabs Cashflow Statement
0.000.00%
Last trade - 00:00- $3.51m
- -$1.03m
- $4.09m
Annual cashflow statement for 20/20 Biolabs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2.07 | 2.19 | -6.39 | -5.13 | -3.74 |
| Depreciation | |||||
| Non-Cash Items | 0.061 | 0.3 | 1.55 | 1.79 | 0.919 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.31 | 3.12 | 0.226 | 0.62 | 0.837 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.15 | 11.6 | -8.96 | -5.2 | -3.84 |
| Capital Expenditures | -0.228 | -0.262 | -0.009 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -0.201 | -0.034 | — | — |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.456 | -0.925 | -0.088 | 0 | — |
| Financing Cash Flow Items | — | -0.012 | -0.148 | 0 | -0.024 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.38 | 0.225 | -0.389 | 0.587 | 2.32 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.114 | 5.45 | -4.72 | -2.31 | -0.758 |